PerkinElmer’s newborn screening platform approved by FDA

PerkinElmer’s AutomatedGSP Genetic Screening Processor – which allows for multi-analyte analysis to accelerate sample screening and increases accuracy – has been approved by the Food and Drug Administration (FDA).

Using the blood from a heel prick, the new system makes it easier for labs to analyse medical conditions in newborns by running more than one test at once on very small samples.

Boasting multi-analyte analysis capability and a two-fold capacity over prior systems, the equipment is able to quantitatively and qualitatively analyse blood spot samples for irregularities associated with metabolic diseases that when detected early, can often be easily treated.

Ann-Christine Sundell, president of genetic screening at PerkinElmer, commented: “This achievement reflects our ongoing commitment, as the global leader in newborn screening, to improving medical outcomes by developing the highest quality newborn screening solutions.”

Earlier this month, PerkinElmer issued an official congratulatory message to its technical partner Brawn GP after its success at the 2009 FIA Formula One Constructors’ and Drivers’ World Championships.